Home
3D Cell Culture
22 February - 23 February 2017
3D Cell Culture

SAE Media Group proudly presents the inaugural launch of 3D Cell Culture, an exciting new conference scheduled to take place on the 22nd and 23rd February 2017, London UK. Following the success of our Advances in Cell Based Assays series, 3D Cell Culture is set to become a leading event for industry. 3D Cell Culture 2017 will address the latest developments of 3D cell culture techniques; the ways in which predictive 3D models are presently paving the way to future technologies, and the ways in which they are currently revolutionizing drug discovery and screening and disease modelling. The 3D cell culture market is predicted to reach $3702.2 million by 2021* with main increase seen in novel technologies and culture methods. This event will highlight emerging technologies, like 3D and 4D bio imaging, and their application in furthering research and medical practice. In addition, there will be focus on organoid technology and the involvement of 3D culture methods in drug and toxicology screening, topics of great current commercial interest to pharmaceutical and research bodies. *Source: http://prn.to/1R0Uq7j

3D Cell Culture 2017 will bring together leading professionals and researchers in the industry to discuss the latest developments and future potential of this technique. 3D Cell Culture 2017 will present success stories 3D culture applications, identifying the newest and brightest technologies, and the translation of 3D models into successful clinical and industrial applications. There will be emphasis on the success and future of 3D methods in organoid research, disease modeling and toxicology screening, stem cell research, and much more.

We look forward to meeting you in February!

FEATURED SPEAKERS

Benedicte Gagny

Benedicte Gagny

Specialiste Application Culture Cellulaire Et Biologie, Sigma Aldrich
Carlo  Cusulin

Carlo Cusulin

Postdoctoral Researcher , Roche
Christopher Schofield

Christopher Schofield

Investigator, GSK
Davide  Danovi

Davide Danovi

Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
Louise Bisset

Louise Bisset

Senior Biologicals Quality Assessor, MHRA
Max Salick

Max Salick

Postdoctoral Researcher, Novartis Institutes For Biomedical Research
Radek Polanski

Radek Polanski

Senior Research Scientist , AstraZeneca
Reyk Horland

Reyk Horland

Head of Business Development, TissUse GmbH
Robert Vries

Robert Vries

Managing Director, Hubrecht Organoid Technology Foundation
Stefan Przyborski

Stefan Przyborski

Professor of Cell Technology, Durham University

Benedicte Gagny

Specialiste Application Culture Cellulaire Et Biologie, Sigma Aldrich
Benedicte Gagny

Carlo Cusulin

Postdoctoral Researcher , Roche
Carlo  Cusulin

Carlo Cusulin is a Postdoctoral fellow in the Disease Relevant Cellular Assays group at Roche innovation center Basel, Switzerland. He obtained his PhD at the University of Lund, Sweden working on neural stem cells in the context of cell replacement for stroke. After that, he did a postdoc in the lab of Prof. Sam Weiss at the University of Calgary, Canada, dealing with cancer stem cells in glioblastoma.
At Roche, Dr. Cusulin utilizes patient-derived stem cells to model Alzheimer's disease in vitro. Together with other members of the group, he is attempting to provide reproducible and scalable cellular models, to be used in drug discovery screens and to understand the pathological processes in a human, physiological context.
 

Christopher Dunsby

Reader in Biomedical Optics, Imperial College
Christopher Dunsby

Chris Dunsby is a Reader with a joint post between Photonics, Department of Physics and the Centre for Histopathology, Department of Medicine at Imperial. His research interests are centred on the application of photonics and ultrafast laser technology to biomedical imaging with an emphasis on quantitative fluorescence imaging, and include light sheet microscopy, multiphoton microscopy, multiparameter fluorescence imaging and fluorescence lifetime imaging.

Christopher Schofield

Investigator, GSK
Christopher Schofield

Chris Schofield is an investigator in the Protein and Cellular Sciences department at GlaxoSmithKline Research and Development, Stevenage. He obtained his undergraduate degree in Applied Biology from the University of Coventry. Joining GlaxoSmithKline in 1995 he has gained over 20 years industrial experience in protein expression supporting small molecule drug discovery. He specialised in development of laboratory and pilot plant scale mammalian and insect cell culture systems including large scale baculovirus, bacMam and other transient systems. His cell culture expertise contributed to the development and implementation of frozen cell technology and the use of frozen isolated mitochondria from cell lines for high throughput screening. He is currently investigating the use of precision cut tissue slices and 3D cell culture models in early drug discovery.

Davide Danovi

Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
Davide  Danovi

Davide Danovi holds an MD from University of Milan and a PhD in Molecular Oncology from the European Institute of Oncology where he demonstrated the causative role of the HdmX protein in human cancer. He completed his postdoctoral training working with Prof. Austin Smith and Dr. Steve Pollard at the University of Cambridge and at University College London where he developed a screening platform to isolate compounds active on human neural stem cells from normal or brain tumour samples. Prior to his current role, he worked as principal scientist at a novel biotechnology company founded to isolate drugs for regenerative medicine using innovative stem cell technologies.

Eleanore Irvine

Business Development Manager , Biogelx Ltd
Eleanore Irvine

Eytan Abraham

Head of Research & Technology for Emerging Technologies, Lonza Incorporated
Eytan Abraham

Dr. Eytan Abraham heads the Emerging Technologies Business Unit Research & Technology (R&T) at Lonza, Inc. The group develops and tests enabling technologies and methods to facilitate manufacturing of cell therapies (allogeneic and autologous), viral therapies, and drug-antibody conjugates for clinical trials and commercial use.
Previously Dr. Abraham was Head of product innovation at the cell therapy company Pluristem Therapeutics.
Dr. Abraham holds a Ph.D. in developmental biology from the University of Maryland and a post-doctorate in tissue engineering and cell therapy at the Harvard-MIT Biomedical Engineering Center (HST) and Harvard Medical School.
 

Louise Bisset

Senior Biologicals Quality Assessor, MHRA
Louise Bisset


Dr Louise Bisset obtained her PhD in Biochemistry (1996) from the University of Newcastle-Upon-Tyne, studying the molecular biology of gene expression where she gained in-depth knowledge of protein production and bioanalytical techniques. This was followed by 5 years as senior research scientist at Protherics Molecular Design Ltd (1996-2001) where she expanded the bioanalytical testing laboratory for the early identification of novel drug candidates. In 2001, Dr Bisset joined the analytical development laboratory of Cancer Research UK (Cancer Research Technology) where she lead a team of assay development scientists engaged in translational research. During that time she developed an interest in regulation and joined the UK’s medicines regulatory agency (the MHRA) as a pharmaceutical assessor in 2008. Dr Bisset is involved in the pre-and post-licensing approval of all types of biological medicinal products, with a special interests in cellular therapies, providing both National and European Scientific Advice.
 

Max Salick

Postdoctoral Researcher, Novartis Institutes For Biomedical Research
Max Salick

Max Salick is a postdoctoral researcher in the Neuroscience Department of the Novartis Institutes for Biomedical Research in Cambridge, USA. Max entered the fields of stem cell biology and disease modeling from an engineering background, having received his PhD from the University of Wisconsin – Madison while researching the biomechanics of stem cell-derived cardiomyocytes. At Novartis, Max has taken a technology-intensive approach to the modeling of developmental neurological diseases. By combining CRISPR engineering, 3D organoid modeling, next-generation sequencing and imaging methods, he is investigating the roles of both genetic and infectious diseases in neurodevelopment. His current focuses are on tuberous sclerosis and the Zika virus, though these techniques are easily adaptable to a wide range of targets.

Nils Goedecke

CEO & Founder, Microduits GmbH
Nils Goedecke

Dr Nils Goedecke is a biophysicist by training and works on microsystem engineering for biological applications since 1996. After finishing his biophysics degree at Humboldt University Berlin he did his PhD in analytical chemistry at Imperial College London focussing on chip-based separation methods. Early 2003 he followed an invitation to work at the Massachusetts Institute of Technology (MIT), where he joined the bioengineering group of Prof P. Matsudaira. There he co-developed a microfluidic chip-based instrument for forensic DNA finger printing. End 2005 he returned to Europe joining the group of Prof A. Hierlemann at ETH Zurich as group leader for microfluidics working on instrumentation for single-cell analysis in systems biology. 2008 his focus returned to microstructured surfaces for cell adhesion guidance and cell mechanics readout. In 2010 he co-founded the ETH spin-off MicroDuits where he leads the product and application development for mechanosensitive cell based assays. Since 2012 he collaborates with Prof Snedekers group at the University Hospital Balgrist with focus on mechano-profiling of bone cancer cells.

Olaf Galuba

Scientist, Novartis Pharmaceuticals
Olaf Galuba

Olaf Galuba grew up in Osnabrück, Lower Saxony in Germany and he studied a Diploma in Engineering (MSc) at the University of Applied Sciences, Jena studying Medical Engineering and Biotechnology. He then began work at Bayer, Wuppertal; where he was a scientist responsible for the development of high throughput screens and ultra-high throughput screening technologies. After 5 years Olaf joined Novartis as part of the lead identification screening group with a special interest in cell based assays and screens identifying modulators of GPCRs. Since 2010 he has been part of a screening group that has focused on target and pathway analysis to support the discovery of novel genes projects trying to discovery new therapies. During this time Olaf was also able to pursue his interesting natural products and target identification for these compounds. Subsequently his role has shifted towards supporting numerous discovery projects for the development of assays to characterize these drug discovery programs, using 3D complex tissue culture systems to more closely reflect the disease being studied.

Peter Banks

Scientific Director, BioTek Instruments Ltd.
Peter Banks

Peter Banks is currently the Scientific Director at BioTek Instruments, Inc. His responsibilities include the management of the company’s applications team and providing scientific guidance to the senior management team on new technology and emerging trends impacting the microplate market and its peripheral markets of liquid handling and detection. Before joining BioTek in 2008, Banks was employed in a number of roles within PerkinElmer for a decade. These roles included management of PerkinElmer’s BioPharma R&D program and Director of Molecular Pharmacology for PerkinElmer BioSignal in Montreal, Canada, focusing on the development of numerous detection technologies and reagent systems for High Throughput Screening. Prior to experiences at PerkinElmer and BioTek, Banks was an Assistant Professor in Analytical Chemistry at Concordia University, Montreal, Canada from 1994 to 1998. Banks was awarded an NSERC post-doctoral fellowship in 1993 following his dissertation for PhD at the University of British Columbia in 1992.

Radek Polanski

Senior Research Scientist , AstraZeneca
Radek Polanski

Radoslaw completed his MSc in Biotechnology in 2005, followed by a PhD in cancer studies in Liverpool researching p53-MDM2 network in kidney cancer. During this time he developed passion for science and pharmacology in particular, which led to a postdoctoral work in the Clinical Experimental Pharmacology lab at the CRUK Manchester Institute working on cell metabolism, circulating tumour cells, cell death and vasculogenic mimicry. A short postdoc at Astrazeneca followed, looking for predictive biomarkers for combination treatments targeting cell death pathways and developing 3D tumour cell models to aid his studies. Radoslaw works in the Cell Biology and Profiling team in the Discovery Sciences in Cambridge, and continues to pursue to develop and apply advanced cell models in the investigation of cancer biology and for drug discovery with particular focus on modeling and elucidation of the mechanisms of drug sensitivity and resistance.

Reyk Horland

Head of Business Development, TissUse GmbH
Reyk Horland

Since 2010 Reyk is actively involved in the development of TissUse’s Multi-Organ-Chip platform for culture analysis of drug candidates, cosmetics, chemicals and consumer products. He currently holds the position of Head of Business Development at TissUse. Prior to TissUse Reyk studied Biotechnology at the Technische Universität Berlin and specialized in Medical Biotechnology. During his academic career he was involved in various tissue engineering programs, all with a focus on commercialisation of the respective products.

Robert Vries

Managing Director, Hubrecht Organoid Technology Foundation
Robert Vries

Dr Robert Vries studied biology in Utrecht (the Netherlands) and Kent University (UK). Subsequently, he got his PhD at the Leiden University Medical Center (The Netherlands) with Prof Dr van der Eb, for the study of gene regulation during oncogenic transformation. He then shifted his interest toward the study of development and stem cells, and joined the group of Gerald Crabtree at Stanford University (USA) to study neural stem cells. In 2007 he returned to the Netherlands to the lab of Prof Dr Hans Clevers to continue the study of stem cells.

The group of Dr Clevers had just discovered the stem cell of intestine in 2007. A breakthrough finding was new protocol for the expansion of intestinal stem cells in culture (organoids). This system formed the basis of protocols that were subsequently developed for other organs such as liver and pancreas but also generated novel disease models such as Cystic Fibrosis, IBD and cancer.

In 2011 Vries changed positions to assist Hans Clevers in the management of his academic group. At the same time he started to work to translate the organoid technology towards clinical and industrial applications. In this capacity he was one of the people who started the foundation Hubrecht Organoid Technology (HUB), of which he is currently the managing director.
 

Samuel Constant

Founder & COO, Epithelix/Oncotheis
Samuel Constant

Dr. Samuel Constant is co-founder and Chief Operating Officer of Epithelix (http://www.epithelix.com) and Chief Executive Officer of OncoTheis (http://www.oncotheis.com) two Swiss biotech companies specialized in tissue engineering.

Epithelix is a leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases. Samuel is in charge of global management and business development of the company; he also deals with the external collaborations with private and public research groups and financial issues.

Within the past 10 years, Dr. Samuel Constant and his team have focused their research efforts on the development of novel in vitro approaches to study effect of inhaled xenobiotics on the human respiratory tract. His efforts have led to the development of methods for repeated toxicity testing of xenobiotics (90 Days repeated dose exposure), evaluation of respiratory absorption and metabolism, assessment of lung inflammation. Since 2006, Dr. Samuel Constant and his team have won 18 prizes for their scientific achievements, technological innovation, and business development.
 

Stefan Przyborski

Professor of Cell Technology, Durham University
Stefan Przyborski

Professor Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, neuroscience and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 100 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of ReproCELL Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. The Company is developing new and innovative ways to manage the growth and function of cultured cells. Its enabling technologies have multiple applications and will be particularly relevant to the control of cell differentiation and function in vitro.

Ute Vespermann

Drug Discovery Specialist, Corning Life Sciences, Europe
Ute Vespermann

Ute Vespermann studied Biology at the University of Münster and received her Ph.D. in Biochemistry and Molecular Biology 1997 at the Max Planck Institute of Biophysical Chemistry in Göttingen. For the last 19 years, Ute is a member of the Corning Life Sciences Team in Europe. She held many different positions in Sales and Marketing and during these years she gained a lot of experience in the fields of Cell Culture, Assay Development, Drug Discovery and HTS. Currently Ute holds a position as Drug Discovery Specialist for Europe.

William Whitford

Strategic Solutions Leader, GE Healthcare
William  Whitford

Bill Whitford is Strategic Solutions Leader, GE Healthcare in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company as an R&D Leader developing products supporting protein biological and vaccine production in mammalian and invertebrate cell lines. Products he has commercialized include defined hybridoma and perfusion cell culture media, fed-batch supplements and aqueous lipid dispersions. An invited lecturer at international conferences, Bill has published over 250 articles, book chapters and patents in the bioproduction arena. He now enjoys such activities as serving on the editorial advisory board for BioProcess International.

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Stefan Przyborski, Professor of Cell Technology, Durham University

clock

9:10

An introduction to 3D methods; Challenges, changes, and the relationships between science and technology

Stefan Przyborski, Professor of Cell Technology, Durham University

• 2D vs 3D cell culture debate
• Review of alternative approaches and the development of new technologies
• Challenges facing 3D culture methods, in terms of technologies available and methods used
• Showcase applications where 3D technology makes a difference
• Future perspective for 3D cell culture technology and further development

 

 

 

clock

9:45

Bridging the gap between 2D and in vivo: tumour spheroid-based assays for target validation and screening

Radek Polanski, Senior Research Scientist , AstraZeneca

• Drug discovery project-related examples of the 2D-3D disconnection with in vivo validation
• Application of a 3D culture technique for analysis of a functional predictive biomarker for the IAPi/TRAIL combination treatment as an alternative to the analysis of expression of single or multiple biomarkers in highly redundant cell death pathways
• Generation of best practice guidelines and development of the platform for screening in tumour spheroids

clock

10:20

Morning Coffee

clock

10:50

Novel tools and techniques for successful 3D cell culture - Corning’s workflow solutions for 3D applications

Ute Vespermann, Drug Discovery Specialist, Corning Life Sciences, Europe

• Advanced Surfaces
• Spheroid Microplates
• Permeable Supports
• Epic Technology

clock

11:25

Developing IPS cell lines for disease modelling

Carlo Cusulin , Postdoctoral Researcher , Roche

• How using IPS cell lines refi nes disease modelling – patient specifi c screens
• Validating 3D models; can we prove that 3D is indeed an improvement and is physiology more relevant than previous methods?
• Overview of STEMBANCC

clock

12:00

Networking Lunch

clock

13:20

HipSci and the ‘Stem cell hotel’, an innovative platforms for collaborative phenotyping

Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London

• Stem cells, high content analysis, drug discovery and disease models
• The ‘Human induced pluripotent stem cells initiative’
• Collaborative phenotyping

clock

13:55

About cancer studies: from research to drug discovery: how 3D technologies are changing the game

Benedicte Gagny

Benedicte Gagny, Specialiste Application Culture Cellulaire Et Biologie, Sigma Aldrich

  • 3D technologies applications: a broad universe
  • From yesterday to now. 3D cancer studies evolution (examples and applications)
  • The specific needs for 3D technologies in drug discovery: existing models
  • What can be the next steps
  • clock

    14:30

    CRISPR engineered organoids for modelling genetic and infectious brain disease

    Max Salick, Postdoctoral Researcher, Novartis Institutes For Biomedical Research

    • Recent genetic advances allow us to rapidly produce isogenically-controlled disease stem cell lines
    • These diseases manifest in cerebral organoids similarly to in the developing human brain
    • Advanced imaging and sequencing methods allow us to closely investigate disease and treatment effects on
    development
    • Similar engineering techniques allow precise investigation of interactions between the specific proteins and
    infectious disease

    clock

    15:05

    Afternoon Tea

    clock

    15:35

    Human in vitro 3D lung models for efficacy and toxicity assessment

    Samuel Constant, Founder & COO, Epithelix/Oncotheis

    • Long term monitoring of effect on respiratory tract
    • Disease models (Asthma; COPD; CF and Lung cancer)
    • How predictive are in vitro 3D human lung models?

    clock

    16:10

    Using 3D spheroids and microtissue methods to investigate hepatotoxicity

    Christopher Schofield, Investigator, GSK

    • Exploring complex culture methods using patient liver cells and tissue
    • How do the 3D models compare to 2D models
    • Moving forward to screening of compounds – how to achieve this?

    clock

    16:45

    Focus session: 3D Bioprinting; current and future value in medicine, research, diagnostics and modelling

    Introduction: What is Bioprinting?
    o How do we distinguish 3D/4D printing, bioprinting, biomaterial printing and biomimetic 4D printing
    Current uses and applications
    • In what applications is bioprinting valuable
    • When will we be ready for codified “Best Practices”
    • Challenges to bioprinting in research, diagnostics, modelling and medicine
    Looking to the future; how do we adopt and implement wide use of 4D Bioprinting methods?
    • Solutions to technical needs and approaches especially for tissues and organs
    • Future approaches to bio-inks, nano-particles, nano-tubes and nano-fibers
    • Cell viability maintenance and post-printing progression
    • Printing resolution, neural and vascular networks
    • Printing cartilage and osteochondral tissues
    • Overcoming challenges to 4D bioprinting
    Discussion – What does the end user really want?
    • Highlighting the gaps between the equipment/materials suppliers and the user; how to produce truly useful technologies
    • Enabling collaboration within the industry

    William Whitford, Strategic Solutions Leader, GE Healthcare

    Eleanore Irvine

    Eleanore Irvine, Business Development Manager , Biogelx Ltd

    clock

    17:45

    Chairman’s Closing Remarks and Close of Day One

    Stefan Przyborski, Professor of Cell Technology, Durham University

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Robert Vries, Managing Director, Hubrecht Organoid Technology Foundation

    clock

    9:10

    EU Regulatory considerations for the use of cells in drug manufacturing (quality focus)

    Louise Bisset, Senior Biologicals Quality Assessor, MHRA

    • Using culture cells in the development and manufacture of medicinal products
    • General regulatory perspective on the use of 3D cultured cells
    • Manufacturing requirements for clinical trials/MAA

    clock

    9:50

    3D organoid cultures: a personalised model for drug discovery as well as companion diagnostics

    Robert Vries, Managing Director, Hubrecht Organoid Technology Foundation

    • Increasing the use of patient-derived cultures in preclinical development has the potential to identify, and eliminate, drugs likely to fail in preclinical trials
    • High failure rates remains one of the greatest challenges, and barriers, to pharmaceutical drug development
    • Using 3D and organoid biobanks to develop preclinical drug development tools and clinical personalised diagnostics
    • The use of organoid models has already lead to successful patient specifi c treatments of Cystic Fibrosis

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Screening of Mouse Intestinal Crypt Cultures: A simple readout for complex biology

    Olaf Galuba, Scientist, Novartis Pharmaceuticals

    • Case study: How mouse intestinal crypt cultures have been adapted to enable high throughput screening
    • In this system, isolated crypts form “organoid structures” with a histological hierarchy recapitulating in vivo small intestinal epithelium were used to screen a focused library of compounds for their ability to help the crypts recover from irradiation
    • A number of challenges facing the implementation of such assays (such as handling Matrigel, the limits of miniaturisation and assay reproducibility) will be discussed
    • Screening allowed the identification of tool compounds with which to help characterise the organoid cultures, subsequently this revealed subtle changes in the organoid response over time. Preliminary characterisation of this change will be described

    clock

    11:40

    Automated workflows for the preparation and quantitative analysis of 3D cell cultures

    Peter Banks, Scientific Director, BioTek Instruments Ltd.

    • Signal transduction assays in a collagen-based scaffold
    • Long term hepatotoxicity in spheroids using primary hepatocytes and iPSC-derived hepatocytes
    • Tumor invasion assays using co-culture spheroids in matrigel
    • Metastatic Cell Migration using 3D bioprinted cells
    • Differentiation of Mesenchymal Stem Cell Spheroids for Downstream Tissue Formation

    clock

    12:20

    Networking Lunch

    clock

    13:30

    Multi-Organ on a chip technologies; potential impact on predictive substance testing

    Reyk Horland, Head of Business Development, TissUse GmbH

    • ‘Human-on-a-chip’ technology allows us to closely study organoid interaction
    • Allows more representative drug toxicity and effi cacy screening. Could this be the end of preclinical trials as we know them?
    • Closing the gap between in vivo and in vitro; the importance of highly physiologically relevant cultures and microenvironments

    clock

    14:10

    Organ printing and the potential of guided angiogenesis

    William Whitford, Strategic Solutions Leader, GE Healthcare

    • Larger printed tissues require cells capable of angiogenesis in order to function, success in achieving functional vasculature has so far been limited
    • Developing both appropriate microfluidics and the in vitro culture media needed for the production of the preimplanted scaffolds remains a challenge
    • Future potential; transplants, regenerative medicine, printing in the fourth dimension

    clock

    14:50

    Leaving 2D behind – considerations and approaches to translating cell therapy manufacturing into 3D

    Eytan Abraham, Head of Research & Technology for Emerging Technologies, Lonza Incorporated

    • Clinical and regulatory implications of transitioning methods from 2D to 3D
    • How does cell type affect optimal method used
    • Manufacturing considerations

    clock

    15:30

    Afternoon Tea

    clock

    16:00

    Automatic mechano-profiling of cells – A new angle on cancer cell assays

    Nils Goedecke, CEO & Founder, Microduits GmbH

    • A short introduction to mechano-biology
    • Basic measuring techniques for cell mechanics – like 3D micro-structured cell culture substrates
    • Automatic mechano-profi ling platform technology (and its potential for bone cancer prognosis)

    clock

    16:40

    Fast 3D imaging in multiwell plates

    Christopher Dunsby, Reader in Biomedical Optics, Imperial College

    • Introduction to light sheet-based fl uorescence microscopy and oblique plane microscopy (OPM) for high speed 3D imaging in multiwell plates
    • Examples of experimental data showing readouts of FRET biosensors in multicellular spheroids, including time-lapse 3D imaging in multiwell plates
    • An overview of initial steps towards developing image
    analysis approaches enabling 3D imaging cytometry in multiwall plates
    • Discussion of future challenges in data analysis, storage and curation

    clock

    17:20

    Chairman’s Closing Remarks and Close of Day Two

    Robert Vries, Managing Director, Hubrecht Organoid Technology Foundation


    Professor of Cell Technology
    Durham University
    Specialiste Application Culture Cellulaire Et Biologie
    Sigma Aldrich
    Postdoctoral Researcher
    Roche
    Reader in Biomedical Optics
    Imperial College
    Investigator
    GSK
    Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,
    King's College London
    Business Development Manager
    Biogelx Ltd
    Head of Research & Technology for Emerging Technologies
    Lonza Incorporated
    Senior Biologicals Quality Assessor
    MHRA
    Postdoctoral Researcher
    Novartis Institutes For Biomedical Research
    CEO & Founder
    Microduits GmbH
    Scientist
    Novartis Pharmaceuticals
    Scientific Director
    BioTek Instruments Ltd.
    Senior Research Scientist
    AstraZeneca
    Head of Business Development
    TissUse GmbH
    Managing Director
    Hubrecht Organoid Technology Foundation
    Founder & COO
    Epithelix/Oncotheis
    Drug Discovery Specialist
    Corning Life Sciences, Europe
    Strategic Solutions Leader
    GE Healthcare

    Sponsors and Exhibitors

    Official Media Partner

    Supporters

    Preliminary Attendee List - February 2017

    Download

    Interview with Novartis

    Download

    Interview with AstraZeneca - Radoslaw Polanski

    Download

    Sponsors and Exhibitors


    BioTek Instruments

    Sponsors and Exhibitors
    http://www.biotek.com/

    BioTek is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation including cell imaging systems, microplate readers, washers, dispensers, automated incubators, stackers and pipetting systems. Our products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications.


    CELLON

    Sponsors and Exhibitors
    http://www.cellon.lu/

    CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements this demanding business sector - which has lead to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specific industry needs - in unique, often revolutionary, ways


    Cellular Dynamics International

    Sponsors and Exhibitors
    http://www.cellulardynamics.com/

    Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and supplier of human cells used in basic and translational research, drug discovery, toxicity testing, and regenerative medicine applications. CDI leverages technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual.


    Corning

    Sponsors and Exhibitors
    http://www.corning.com/lifesciences

    Corning is a global manufacturer of tools and equipment for cell culture, genomics, drug discovery, and microbiology. Our Corning®, Falcon®, Axygen®, and Gosselin™ brands include: vessels and differentiated surfaces for cell culture and scale-up, media, liquid handling products, ADME/Tox products and services, and microbiology consumables.


    Jellagen

    Sponsors and Exhibitors
    http://www.jellagen.co.uk/

    Jellagen Pty Ltd is a Med-Tech business manufacturing next generation collagen products sourced from Jellyfish for application in 2D and 3D cell culture and medical devices. Jellagen’s research grade materials are distributed into the global cell culture and stem cell research markets. Jellagen’s collagen products offers the potential of in vitro to in vivo applications as well as batch to batch consistency offering advantages to research and medical applications.


    Merck

    Sponsors and Exhibitors
    http://www.merckmillipore.com/

    Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials with about 50,000 employees in 66 countries. The organization has extensive expertise in 3D cell culture including Organotypic cell culture inserts, specialty cells, matrices and instrumentation.


    Nexcelom

    Sponsors and Exhibitors
    http://www.nexcelom.co.uk

    Nexcelom’s Cellometer and Celigo S image cytometry products are designed for cell analysis in life science and biomedical research. The Cellometer instruments cover basic cell counting, viability and cell-based assays with 20uL of sample. The Celigo S is a high throughput fast micro-well 2D and 3D image cytometer. Nexcelom products are help researchers all over the world.


    Thermo Fisher Scientific

    Sponsors and Exhibitors
    http://www.thermofisher.com/

    As a worldwide leader in serving science, Thermo Fisher Scientific invites you to partner with us to reach your RNA therapeutic development goals. Explore our portfolio of high-quality TheraPure reagents designed for your oligonucleotide and mRNA synthesis to help you move your project from development to manufacturing and commercialization. Accelerate your productivity and innovation with expertise, services, and support from Thermo Fisher Scientific.

    Media Partners


    Assay and Drug Development Technologies

    Official Media Partner
    http://www.liebertpub.com/overview/assay-and-drug-development-technologies/118/

    Assay and Drug Development Technologies delivers access to the techniques and tools that enable new advances in early-stage screening, and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application.

    Media Partners


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    G.I.T. Laboratory Journal

    Supporters
    http://www.gitverlag.com/go/glj

    G.I.T. Laboratory Journal Europe vovers chromatography, mass spectrometry, spectroscopy and digital imaging, as well as laboratory IT, laboratory equipment and automation in all fields of application. As a consequence of the increasing overlap in all scientific disciplines in academic and industrial research the magazine also sets a strong focus on Life Sciences. • features up-to-date scientific articles • presents current trends in laboratory instrumentation and application • reveals recent developments in the drug discovery and pharmaceutical industry, contract research and clinical testing


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.